So Hee Kwon

Dr. So Hee Kwon

College of Pharmacy, Yonsei Institute of Pharmaceutical Sciences, Yonsei University, Incheon, 21983, South Korea
orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 December 2012 in The FEBS Journal
Verified
Journal Article
Closed access
PDF file
YLYingxiu Li
Yingxiu Li
DSDonghee Shin
Donghee Shin
So Hee KwonSo Hee Kwon
So Hee Kwon

Verified
Journal Article
Open access
PDF file
GKGO WOON KIM
GO WOON KIM
DLDong Hoon Lee
Dong Hoon Lee
YJYu Hyun Jeon
Yu Hyun Jeon
JYJung Yoo
Jung Yoo
SKSo Yeon Kim
So Yeon Kim
So Hee KwonSo Hee Kwon
So Hee Kwon
The significance of glutamine in cancer metabolism has been extensively studied. Cancer cells consume an excessive amount of glutamine to facilitate rapid proliferation. Thus, glutamine depletion occurs in various cancer types, especially in poorly vascularized cancers. This makes glutamine synthetase (GS), the only enzyme responsible for de novo synthesizing glutamine, essential in cancer metabolism. In cancer, GS exhibits pro-tumoral features by synthesizing glutamine, supporting nucleotide synthesis. Furthermore, GS is highly expressed in the tumor microenvironment (TME) and provides glutamine to cancer cells, allowing cancer cells to maintain sufficient glutamine level for glutamine catabolism. Glutamine catabolism, the opposite reaction of glutamine synthesis by GS, is well known for supporting cancer cell proliferation via contributing biosynthesis of various essential molecules and energy production. Either glutamine anabolism or catabolism has a critical function in cancer metabolism depending on the complex nature and microenvironment of cancers. In this review, we focus on the role of GS in a variety of cancer types and microenvironments and highlight the mechanism of GS at the transcriptional and post-translational levels. Lastly, we discuss the therapeutic implications of targeting GS in cancer.

12 January 2017 in Oncotarget
Verified
Journal Article
Open access
PDF file
DLDong Hoon Lee
Dong Hoon Lee
HRHyun-Wook Ryu
Hyun-Wook Ryu
HWHye-Rim Won
Hye-Rim Won
So Hee KwonSo Hee Kwon
So Hee Kwon
Glioblastoma multiforme (GBM) is the most lethal primary brain tumor in adults despite contemporary gold-standard first-line treatment strategies. This type of tumor recurs in virtually all patients and no commonly accepted standard treatment exists for the recurrent disease. Therefore, advances in all scientific and clinical aspects of GBM are urgently needed. Epigenetic mechanisms are one of the major factors contributing to the pathogenesis of cancers, including glioblastoma. Epigenetic modulators that regulate gene expression by altering the epigenome and non-histone proteins are being exploited as therapeutic drug targets. Over the last decade, numerous preclinical and clinical studies on histone deacetylase (HDAC) inhibitors have shown promising results in various cancers. This article provides an overview of the anticancer mechanisms of HDAC inhibitors and the role of HDAC isoforms in GBM. We also summarize current knowledge on HDAC inhibitors on the basis of preclinical studies and emerging clinical data.

31 March 2015 in Toxicological Research
Verified
Journal Article
Open access
HRHyun-Wook Ryu
Hyun-Wook Ryu
DLDong Hoon Lee
Dong Hoon Lee
HWHye-Rim Won
Hye-Rim Won
KKKyeong Hwan Kim
Kyeong Hwan Kim
YSYun Jeong Seong
Yun Jeong Seong
So Hee KwonSo Hee Kwon
So Hee Kwon
Environmental toxicants such as toxic metals can alter epigenetic regulatory features such as DNA methylation, histone modification, and non-coding RNA expression. Heavy metals influence gene expression by epigenetic mechanisms and by directly binding to various metal response elements in the target gene promoters. Given the role of epigenetic alterations in regulating genes, there is potential for the integration of toxic metal-induced epigenetic alterations as informative factors in the risk assessment process. Here, we focus on recent advances in understanding epigenetic changes, gene expression, and biological effects induced by toxic metals.

1 April 2017 in Cancer Letters
Verified
Journal Article
Closed access
HRHyun-Wook Ryu
Hyun-Wook Ryu
DSDong-Hee Shin
Dong-Hee Shin
DLDong Hoon Lee
Dong Hoon Lee
JCJunjeong Choi
Junjeong Choi
GHGyoonhee Han
Gyoonhee Han
So Hee KwonSo Hee Kwon
So Hee Kwon

9 October 2022 in Cells
Verified
Journal Article
Open access
PDF file
JKJiyoon Kim
Jiyoon Kim
HCHayoung Cho
Hayoung Cho
JYJung Yoo
Jung Yoo
GKGO WOON KIM
GO WOON KIM
YJYu Hyun Jeon
Yu Hyun Jeon
So Hee KwonSo Hee Kwon
So Hee Kwon
Histone deacetylase 8 (HDAC8) is a class I HDAC that catalyzes the deacetylation of histone and non-histone proteins. As one of the best-characterized isoforms, numerous studies have identified interacting partners of HDAC8 pertaining to diverse molecular mechanisms. Consequently, deregulation and overexpression of HDAC8 give rise to diseases. HDAC8 is especially involved in various aspects of cancer progression, such as cancer cell proliferation, metastasis, immune evasion, and drug resistance. HDAC8 is also associated with the development of non-cancer diseases such as Cornelia de Lange Syndrome (CdLS), infectious diseases, cardiovascular diseases, pulmonary diseases, and myopathy. Therefore, HDAC8 is an attractive therapeutic target and various HDAC8 selective inhibitors (HDAC8is) have been developed. Here, we address the pathological function of HDAC8 in cancer and other diseases, as well as illustrate several HDAC8is that have shown anti-cancer effects.